What is the clinical evidence from this study?

Study design: Cohort. Population: Prostate cancer receiving androgen deprivation therapy after radical prostatectomy (n=1274). Intervention: Statin use vs. No statin use. Primary outcome: All-cause mortality (time-varying statin use) (HR 0.51, 95% CI 0.40, 0.64, p=<0.001).

What question did this study set out to answer?

To evaluate the association between statin use and prostate cancer outcomes in patients receiving androgen deprivation therapy after radical prostatectomy.

May 29, 2026Journal of Clinical Oncology

Does a statin a day keep prostate cancer (PC) away?: Statin use and disease progression in patients receiving androgen deprivation therapy (ADT) after radical prostatectomy (RP) in SEARCH.

Q: What are the key findings of this study?

Time-dependent statin use during androgen deprivation therapy was associated with significantly lower risks of all-cause mortality (HR 0.51; 95% CI 0.40-0.64; P<0.001) and disease progression.

Q: What does this research mean for the field?

When evaluated as a time-dependent variable to account for initiation during treatment, statin use during androgen deprivation therapy is associated with significantly lower rates of castration-resistant prostate cancer, prostate cancer-specific mortality, and all-cause mortality. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To evaluate the association between statin use and prostate cancer outcomes in patients receiving androgen deprivation therapy after radical prostatectomy.

View Full Paper

Ask AI

Bookmark

Why the study?

Prior studies suggested statins may improve prostate cancer outcomes during androgen deprivation therapy (ADT), but they compared statin use only at ADT initiation, ignoring subsequent initiation.

Does statin use reduce disease progression and mortality in prostate cancer patients receiving androgen deprivation therapy after radical prostatectomy?

Population

1,274 prostate cancer patients receiving ADT after radical prostatectomy at 9 VA hospitals

Comparison

Statin users vs non-users (evaluated at baseline and as a time-dependent exposure)

Design

Retrospective cohort study

Key result

Time-dependent statin use during androgen deprivation therapy was associated with significantly lower risks of all-cause mortality (HR 0.51; 95% CI 0.40-0.64; P<0.001) and disease progression.

Authors

MMMaria P. Mogollon JJJessica Janes ZKZachary Klaassen

Discussion

Member takes

Overview

Statin use was associated with delayed CRPC and reduced PCSM; hypothesis-generating and requires randomized confirmation before clinical adoption.

Key Points

To evaluate the association between statin use and prostate cancer outcomes in patients receiving androgen deprivation therapy after radical prostatectomy.
Retrospective cohort study of 9,931 prostate cancer patients treated from 1988 to 2020 at 9 VA hospitals.
Patients receiving ADT for biochemical recurrence after 2000 were included and analyzed based on statin use at the time of ADT and as a time-dependent covariate.
Cox models assessed the relationship between statin use and outcomes like time to metastasis and prostate cancer-specific mortality.
Statin use at ADT showed no significant association with time to metastasis or PCSM (HRs 0.89-0.98, all p>0.2).
Time-dependent analysis indicated lower risk of castration-resistant prostate cancer (CRPC, p=0.019) and prostate cancer-specific mortality (PCSM, p=0.020) for statin users.
Trend towards reduced metastasis was observed (p=0.058) with time-dependent statin use.

Study Design

Type

Cohort (n=1,274)

Multicenter

Yes

Structured PICO

Does statin use reduce disease progression and mortality in prostate cancer patients receiving androgen deprivation therapy after radical prostatectomy?

Population

1,274 patients with prostate cancer receiving androgen deprivation therapy (ADT) for biochemical recurrence after radical prostatectomy (RP) at 9 VA hospitals.

Intervention

Statin use (evaluated as baseline use at ADT initiation and as a time-dependent covariate)

Comparator

No statin use

Outcome

Time to metastasis, castration-resistant prostate cancer (CRPC), prostate cancer specific mortality (PCSM), and all-cause mortality (ACM)hard clinical

Main Result

Effect estimate: HR 0.51 (95% CI 0.40, 0.64)

p-value: p=<0.001

When accounting for time-dependent initiation, statin use during androgen deprivation therapy is associated with significantly lower rates of castration-resistant prostate cancer and mortality.

Cite This Study

Mogollon et al. (2026) conducted a cohort in Prostate cancer receiving androgen deprivation therapy after radical prostatectomy (n=1,274). Statin use vs. No statin use was evaluated on All-cause mortality (time-varying statin use) (HR 0.51, 95% CI 0.40, 0.64, p=<0.001). Time-dependent statin use during androgen deprivation therapy was associated with significantly lower risks of all-cause mortality (HR 0.51; 95% CI 0.40-0.64; P<0.001) and disease progression.

synapsesocial.com/papers/6a192f88fab5b468c4418b2f https://doi.org/10.1200/jco.2026.44.16_suppl.5091

View Full Paper

Ask AI

Bookmark

May 29, 2026Journal of Clinical Oncology

Does a statin a day keep prostate cancer (PC) away?: Statin use and disease progression in patients receiving androgen deprivation therapy (ADT) after radical prostatectomy (RP) in SEARCH.

View Full Paper

Ask AI

Bookmark

Why the study?

Prior studies suggested statins may improve prostate cancer outcomes during androgen deprivation therapy (ADT), but they compared statin use only at ADT initiation, ignoring subsequent initiation.

Does statin use reduce disease progression and mortality in prostate cancer patients receiving androgen deprivation therapy after radical prostatectomy?

Population

1,274 prostate cancer patients receiving ADT after radical prostatectomy at 9 VA hospitals

Comparison

Statin users vs non-users (evaluated at baseline and as a time-dependent exposure)

Design

Retrospective cohort study

Key result

Time-dependent statin use during androgen deprivation therapy was associated with significantly lower risks of all-cause mortality (HR 0.51; 95% CI 0.40-0.64; P<0.001) and disease progression.

Authors

MMMaria P. Mogollon JJJessica Janes ZKZachary Klaassen

Discussion

Member takes

Overview

Statin use was associated with delayed CRPC and reduced PCSM; hypothesis-generating and requires randomized confirmation before clinical adoption.

Key Points

To evaluate the association between statin use and prostate cancer outcomes in patients receiving androgen deprivation therapy after radical prostatectomy.
Retrospective cohort study of 9,931 prostate cancer patients treated from 1988 to 2020 at 9 VA hospitals.
Patients receiving ADT for biochemical recurrence after 2000 were included and analyzed based on statin use at the time of ADT and as a time-dependent covariate.
Cox models assessed the relationship between statin use and outcomes like time to metastasis and prostate cancer-specific mortality.
Statin use at ADT showed no significant association with time to metastasis or PCSM (HRs 0.89-0.98, all p>0.2).
Time-dependent analysis indicated lower risk of castration-resistant prostate cancer (CRPC, p=0.019) and prostate cancer-specific mortality (PCSM, p=0.020) for statin users.
Trend towards reduced metastasis was observed (p=0.058) with time-dependent statin use.

Study Design

Type

Cohort (n=1,274)

Multicenter

Yes

Structured PICO

Does statin use reduce disease progression and mortality in prostate cancer patients receiving androgen deprivation therapy after radical prostatectomy?

Population

1,274 patients with prostate cancer receiving androgen deprivation therapy (ADT) for biochemical recurrence after radical prostatectomy (RP) at 9 VA hospitals.

Intervention

Statin use (evaluated as baseline use at ADT initiation and as a time-dependent covariate)

Comparator

No statin use

Outcome

Time to metastasis, castration-resistant prostate cancer (CRPC), prostate cancer specific mortality (PCSM), and all-cause mortality (ACM)hard clinical

Main Result

Effect estimate: HR 0.51 (95% CI 0.40, 0.64)

p-value: p=<0.001

When accounting for time-dependent initiation, statin use during androgen deprivation therapy is associated with significantly lower rates of castration-resistant prostate cancer and mortality.

Cite This Study

synapsesocial.com/papers/6a192f88fab5b468c4418b2f https://doi.org/10.1200/jco.2026.44.16_suppl.5091

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark